The insurer reported first-quarter profit of $1.65bn, adjusted EPS of $7.79 and revenue of $68.49bn, topping analyst forecasts as medical costs came in lower.
Revenue rose 5%, helped by 9% adjusted revenue growth at Evernorth Health Services, whose pharmacy-benefit business offset the earlier divestiture of Cigna's Medicare operations.
Despite the earnings beat and higher 2026 guidance, Cigna shares fell 3% in the prior session as investors remained cautious about pharmacy-benefit pressures and demanded clearer evidence of sustained growth.
Can Cigna's new CEO maintain profits while overhauling the company's core business model?
Will Cigna's 'rebate-free' plan lower drug costs or just shift them into higher insurance premiums?
Is Cigna’s bold reform the beginning of the end for the entire American drug rebate system?
Beyond the FTC settlement, how will Cigna address the lawsuit alleging a massive rebate diversion scheme?
How will drug makers react when high list prices no longer guarantee preferential PBM treatment?